Summary Melatonin (aMT) appears to be a potentially important oncostatic substance that can block the mitogenic effects of tumour-promoting hormones and growth factors such as oestradiol and epidermal growth factor, in vitro. In the present study, we examined the possibility that aMT would also inhibit the stimulatory effects of the tumour-promoter prolactin (PRL) on MCF-7 and ZR75-1 human breast cancer cell (HBC) growth under 5% charcoal-stripped fetal bovine serum culture conditions. Human PRL (10-100ng ml-') stimulated the rate of MCF-7 and ZR-75-1 HBC growth up to 2-fold above that of untreated controls. Melatonin, at concentrations between 1012-M and 10-5M, diminished and at physiological levels completely abolished PRL's mitogenic activity, but had no effect on growth in the absence of PRL. The mitogenic effects of human growth hormone (hGH), a PRL-related hormone, and also of several monoclonal antibodies (MAbs) against the PRL receptor (PRLR), were also abrogated by physiological concentrations of aMT. Additionally, aMT blocked the enhancement of MAb mitogenic activity induced by a second 'cross-linking' antibody (CLA). These findings indicate that aMT interrupts the PRLR-mediated growth signal in HBC and suggest that the oncostatic activity of aMT may also be linked with an antagonism of PRL's actions.
Melatonin (aMT), the chief hormone from the pineal gland (Reiter, 1991) , appears to be an important inhibitor of cancer (Blask, 1993) . Over the past decade a considerable amount of evidence has accumulated suggesting that aMT has potent antineoplastic properties, particularly with respect to the development of breast neoplasms . For example, several workers have shown that exogenously administered aMT impedes chemically induced mammary tumorigenesis in rodents (Aubert et al., 1980; Kothari et al., 1984; Blask et al., 1991) . Moreover, the reduction of aMT in the blood, via surgical or functional pinealectomy, enhances carcinogenesis in susceptible animals but not those given aMT (Tamarkin et al., 1981; Shah et al., 1984) . In addition, aMT impedes the growth of human breast cancer cells in vitro (Hill and Blask, 1988; Shellard et al., 1989; Cos and Blask, 1990) and breast tumours transplanted into rats (Karmali et al., 1978) . Since these results suggest that circulating aMT in the blood may impart some protection against mammary tumorigenesis and that established tumours retain their sensitivity to aMT's cytostatic effects, it has been postulated that breast cancer may respond favourably to aMT therapy (Karmali et al., 1978) . These ideas are also supported by aMT's ability to reduce the circulating levels and/or activity of mammogenic hormones such as oestrogen and prolactin (PRL) (Reiter, 1980; Blask and Leadem, 1987) , both of which stimulate breast cancer growth (Welsch, 1985; Rose and Noonan, 1989) . One of the most interesting aspects of aMT's anti-cancer activity is its ability to inhibit the growth of the tumour cell itself by blocking the stimulatory effects of other hormones and growth factors. For example, recent studies have shown that aMT can inhibit human breast cancer cell (HBC) proliferation by blocking the mitogenic actions of both oestradiol and epidermal growth factor (Cos et al., 1991; Hill et al., 1992; Cos and Blask, 1994) , and causing a delay at the GO/G, stage of the cell cycle (Cos et al., 1991) .
In this study, we examined aMT's potential for blocking the mitogenic actions of PRL on HBCs grown in culture. The examination of aMT inhibition of PRL's mitogenic action, albeit not previously studied, is warranted, based on aMT's ability to inhibit PRL-dependent mammary tumours in vivo (Tamarkin et al., 1981; Shah et al., 1984; 1991; Subramanian and Kothari, 1991) and on the increasing concern that PRL promotes breast malignancies in humans (Bonneterre et al., 1987; Shiu et al., 1987; Boutin et al., 1989) as it does in rodents (Welsch, 1985) . The effects of aMT on PRL-stimulated HBC growth were studied in the MCF-7 and ZR-75-1 oestrogen receptor (ER)-positive HBC models because of the widespread use of these cells and their established sensitivity to PRL under defined (lactogen-deficient) serum conditions Vonderhaar and Biswas, 1987; Vonderhaar, 1989) .
We also tested aMT's ability to inhibit the mitogenic activity of a PRL-related hormone, human growth hormone (hGH), as well as the mitogenic effects of several mouse monoclonal antibodies (MAbs) directed against the PRL receptor (PRLR) (Kelly et al., 1988; Eldberg et al., 1990 ). The MAbs were tested by themselves and also in combination with a second antibody that boosts the mitogenic actions of the MAbs, resulting in a further increase in proliferation (Eldberg et al., 1990) . These additional studies helped clarify aMT's anti-PRL action since both hGH hPRL-1-6, >99.9% purity) and Human GH (NIDDK-hGH-B-1) were generous gifts from Dr Salvatore Raiti of the National Pituitary Hormone Program. Monoclonal antibodies to the PRLR were those described previously (Kelly et al., 1988 ) that have been shown to cross-react with the human PRLR (Eldberg et al., 1990) . Rabbit antiserum to mouse immunoglobulin G was purchased from Calbiochem (La Jolla, CA, USA).
Culture techniques
MCF-7 and ZR-75-1 cells were maintained and routinely subpassaged in Dulbecco's modified Eagle medium (DMEM) supplemented with penicillin (200 U ml '), streptomycin (200 jLg ml-'), and 10% fetal bovine serum (FBS), at 37°C in a humid atmosphere containing 5% carbon dioxide. Before growth studies, cells were grown for at least 4 days in 10% charcoal-stripped FBS (CSS) to minimise the carry-over of bovine lactogens into the experiments.
Preparation of charcoal-stripped serum A modification of the charcoal-stripping methods of Lippman et al. (1976) was used in the present study. Briefly, Norit A charcoal was repeatedly washed first with 1 M hydrogen chloride then with phosphate-buffered saline (PBS) containing 1 mg ml-' of Dextran T-70 pH 7.2. The charcoal suspension was then dried in an oven overnight and 25 mg of dextran-coated charcoal was added to 500 ml of FBS at 56°C for 30 min. This suspension was then centrifuged at 10000 g for 45 min and prefiltered through a millipore glass fibre filter. The serum was then re-exposed to dextran-coated charcoal for 1-2 additional cycles in order to further reduce its lactogen content. The CSS was sterilised by passage through a 0.22 LLM millipore filter and then stored at -20°C until needed. This procedure reduced the bovine lactogen content of the serum by 98% (<3 ng ml-') as determined by radioimmunoassay (RIA). In addition, 83% of the endogenous oestrogens were removed as determined by RIA.
In vitro cell growth studies Cells were harvested from 70-80% confluent cultures and reseeded onto 60 mm x 15 mm Falcon plates at a density of 3 x 105 cells/plate. DMEM supplemented with 5% lactogendeficient CSS and 2% antibiotics was used for the culture of both MCF-7 and ZR-75-1 cells. After 24 h the medium was replaced with fresh DMEM containing either vehicle, hormones and/or MAbs. Melatonin was dissolved in ethanol (EtOH) then diluted with medium to 10-12 -0-M. The level of EtOH carried over into the studies was not more than 0.035% (vehicle control). The cells were allowed to grow for up to 6 days in this medium. Cell number for triplicate plates for each treatment was determined with a haemocytometer after detachment of the cells with PBS/EDTA and their passage through a 25 gauge syringe. Cell viability (>95%) was assessed by the trypan blue exclusion test. A mean growth rate from triplicate plates was calculated based on cell number. The growth rate was equal to the difference between the initial number of cells seeded per plate and the number of cells found at a particular time point, at any time from h, divided by the initial cell number. For comparisons between groups the mean rate of growth in each treatment group was graphed as a per cent of control growth rate. Unless otherwise stated the data are expressed as the mean of three independent experiments.
For the PRL dose-response studies 20-100ngml1' of hormone was used, the other experiments used only the 20 ng ml' dose. In the hGH dose-response studies 20-100ngml-' of hormone was used. In the MAb studies, MAbs T1, T6, U5, U6 or E21 were each used at a final concentration of 0.62 nM. In the experiments with the CLA, a dilution of 1:1250 was used because it was the most effective at enhancing the mitogenic activities of the TI and T6 MAbs.
Statistical analysis Mean ± (s.e.m.) growth rate for hormone-treated cells was expressed as a per cent of the control growth rate (100%). All data were analysed with a one-way ANOVA and statistical differences among mean values were determined by Student Newman-Keuls post hoc test. Differences between and among means were considered significant at P<0.05.
Results
Dose-response of HBC growth to PRL in the presence or absence of aMT As shown in Figure la and b, PRL, at concentrations ranging from 20 to 100 ng ml1', significantly increased the rate of MCF-7 and ZR-75-1 cell growth as compared with untreated controls when cells were grown for 3 days as monolayer cultures in medium supplemented with 5% CSS and hormone. A physiological dose of PRL (20 ng ml1') caused the greatest increase (2-fold) in both MCF-7 and ZR-75-1 cell growth as compared with untreated control.
Melatonin ( with aMT (10-9M) and PRL at a dose of 20ngmlV-was equivalent to that of controls, indicating that the stimulatory effect of PRL on growth was completely abolished by aMT. Even greater reductions in growth, below the levels in vehicle controls, were seen in ZR-75-1 cells exposed for longer periods (5-6 days) to aMT plus PRL (data not shown). However, aMT in the absence of PRL had no effect on growth in both MCF-7 and ZR-75-1 cells.
Temporal effects of aMT plus PRL on HBC growth Figure 2 shows the growth response of MCF-7 cells to PRL (20ngml-') and/or aMT (10-9M) over a 6 day incubation period. The highest rate of growth (2-fold greater than control) was seen in PRL-treated cells on the 3rd day of incubation. This high level of growth could be maintained throughout the culture period by adding fresh hormone and medium on days 2 and 4 of the experiment (not shown). Otherwise, on days 4 and 6, PRL increased growth 1.5-fold and 1.2-fold respectively, as compared with untreated controls (shown). In contrast, there was no increase seen in the growth of cells treated with PRL plus aMT throughout the incubation period. In fact, the growth rate tended to be lower than that of the vehicle-treated controls at each time point tested. Again, aMT in the absence of PRL had no effect on growth over the course of the study. each of the concentrations tested, did not significantly alter growth with the exception of the 10-6 M concentration. This high level of aMT increased growth by an average of 50% as compared with untreated controls (data not shown).
Dose-response of HBC to human GH in the presence or absence of aMT The mitogenic response of MCF-7 cells to increasing concentrations of human GH (25-100 ng ml') in the presence or absence of aMT is shown in Figure 4 . Human GH, at each concentration tested, significantly increased growth by as much as 80% when compared with untreated controls. However, in cells exposed simultaneously to human GH and aMT the rate of growth was significantly less than that seen with GH alone. In fact, the growth of cells treated with GH at 25 ng ml-plus aMT was reduced to the untreated control level. In contrast, aMT in the absence of GH had no effect on growth. Figure 5 demonstrates the mitogenic response of MCF-7 cells to several different MAbs directed against the PRLR following a 3 day incubation period. The growth rates of cells treated with the MAbs TI, T6, U5, U6 or E21 (0.62 nM) were 1.7-, 1.5-, 1.4-, 1.8-and 1.4-fold higher, respectively, than that of the controls. Interestingly, both TI and U6 increased growth by an amount that was not significantly different from that seen with the native ligand while a nonspecific mouse IgG had no effect on growth (data not shown).
Mitogenic effects of MAbs on HBC
with U5, CLA plus aMT was reduced to the level observed with U5 alone. Hence, aMT diminished the activity of the MAbs even in the presence of CLA. Since CLA had no effect on U6 (0.62 nM)-stimulated growth, this treatment group was excluded from the study.
Discussion
Under the appropriate culture conditions, MCF-7 and ZR-75-1 human breast cancer cells are sensitive to a number of different mitogens including the pituitary hormone PRL (Biswas Vonderhaar, 1989) . In the present study, we used these specific culture conditions (5% CSS) to investigate the possibility that aMT would inhibit Effects of aMT on MAb-stimulated HBC growth The stimulatory growth response of MCF-7 cells to TI in the presence of aMT is depicted in Figure 6 . TI (0.62 nM) increased growth 1.6-fold as compared with controls. In cells treated with aMT (10-9M) plus TI, the growth rate was significantly less than that found in TI-treated cells and was almost equal to that of controls. U6 (0.62 nM) also increased growth 1.9-fold as compared with controls. However, in cells treated with U6 plus aMT growth was significantly reduced to almost that of controls. Monoclonal antibody U5 (0.62 nM) caused a similar enhancement of growth, but to a lesser extent than did TI or U6. The growth rate in cells incubated with U5 plus aMT was reduced to that of controls as well.
Effects of aMT on CLA-enhanced MAb-stimulated HBC growth Figure 7 shows the second cross-linking antibody's (CLA) ability to enhance the activities of the MAbs TI and U5. TI (0.62 nM) plus CLA (1:1250 dilution) increased growth 1.9-fold as compared with untreated controls and was approximately 25% greater than the rate seen with TI alone. Similarly, U5 alone increased growth 1.4-fold as compared with control, while U5 plus CLA increased growth 2-fold as compared with untreated controls. This was 40% above the level observed with U5 alone. In cells exposed simultaneously to TI, CLA and aMT (10-9M) the rate of growth was reduced to vehicle control levels, while growth in cells treated Figure 7 The effects of aMT on CLA-enhanced MAb-stimulated MCF-7 cell proliferation. MCF-7 cells were exposed to MAb Tl or U5 (0.62 nM) plus either CLA (rabbit IgG) (1:1250 dilution) or CLA and aMT (10-9 M) for 3 days, harvested and then counted as described in Material and methods. Growth was expressed as a percent of vehicle-treated control (CTL) (100%). Bars represent the mean (± s.e.m.) of two independent experiments. *P<0.05 vs MAb plus CLA.
the mitogenic response of these human breast cancer cell lines to human PRL. In addition, we tested aMT's ability to inhibit the mitogenic activity of human GH, a homologous mammogenic hormone which can stimulate MCF-7 cell proliferation via the PRLR ). Moreover, we tested aMT's potential ability to inhibit the 'PRL-like' activity of several different MAbs directed against the PRLR (Kelly et al., 1988; Eldberg et al., 1990) . As anticipated on the basis of earlier studies (Biswas and Vonderhaar and Biswas, 1987; Vonderhaar, 1989) , we found that human PRL stimulated the growth of MCF-7 and ZR-75-1 cells under lactogen-deficient media conditions. A physiological concentration of PRL (20 ng mlP") elicited the best stimulation of cell growth in both cell lines. The degree of stimulation (2-fold) was within the range (1.5-to 3.0-fold) typically observed by us, but was less than the maximum mitogenic response (greater than 3-fold) reported previously by Biswas and Vonderhaar (1987) . The difference in sensitivity to PRL in our study may relate to differences in the lot of FBS used, the charcoalstripping process, and/or to a different clone of MCF-7 cells. These factors may also have contributed to the failure of some workers to observe a growth response of MCF-7 cells to PRL (Shiu, 1981; Jozan et al., 1982; Shafie and Brooks, 1977; Kelly et al., 1989) , which has been discussed in detail elsewhere .
When MCF-7 cells were exposed simutaneoulsy to physiological levels of human PRL and aMT, the mitogenic response to PRL was blocked at each of the time points tested. In fact, in one instance the addition of aMT significantly reduced the rate of cell growth below untreated control levels indicating that PRL may actually increase MCF-7 cell sensitivity to the inhibitory effects of aMT. We previously suggested a similar notion to explain PRL's ability to restore aMT's oncostatic activity under serum-free medium conditions (Blask and Hill, 1986) . Not surprisingly, aMT in the absence of mitogen did not affect cell growth as compared with untreated controls, under these culture conditions. This finding is consistent with an earlier report that aMT depends on serum factors for its anti-proliferative activity in MCF-7 cells (Blask and Hill, 1986 al., 1981; Shah et al., 1984; Blask et al., 1991, Subramanian and Kothari, 1991) in vivo is due partly to its ability to inhibit PRL's mitogenic actions. Moreover, our demonstration that aMT inhibits breast cancer growth at physiologically relevant concentrations lends additional support to the notion that aMT may be a naturally occurring oncostatic hormone (Blask, 1993) . The suppressive effect of aMT on mammary tumour growth is reminiscent of its inhibitory influence on mammary gland development during puberty in other mammalian species (Sanchez-Barcello et al., 1990 , 1991 . Hence, the nocturnal pineal secretion of aMT may be part of a normal regulatory mechanism suppressing mammary growth that persists during malignancy and is therefore of clinical relevance.
